Prevalence and risk factors for long COVID after mild disease: a longitudinal study with a symptomatic control group

BACKGROUND

Long COVID has received less attention from the scientific community than acute COVID-19, representing less than 2% of COVID-19 publications in PubMed Clinical Queries, August 31, 2022). Several important aspects remain undefined such as its prevalence. Long COVID has been reported to effect between 7.5% to 89% of patients [1, 2, 29, 30]. Most of these studies do not include well-matched controls which is important because long COVID-symptoms are nonspecific and may be attributed to other factors such as the physical and mental impact of having COVID-19 infection or hospitalization [3,4]. Prospective studies enrolling symptomatic individuals with and without confirmed COVID-19 are necessary to better estimate the prevalence of long COVID and its associated risk factors.

Long COVID is anticipated to have a large impact on the healthcare system [5]. Identifying risk factors for developing long COVID will help mitigate its impact. Some risk factors have been suggested for long COVID; however, these studies consisted of previously hospitalized patients [1] or were retrospective analyses from electronic health records of not hospitalized patients (31). We therefore performed a longitudinal study of patients with COVID-like symptoms who tested positive or negative for SARS-CoV-2 to assess the prevalence and risk factors for long COVID and its impact on the quality of life.

METHODS

RESULTS

In total, 1,268 patients with suspected SARS-CoV-2 infection were recruited and answered the first questionnaire 4 days (range of 3-5 days) post symptom onset. After excluding cases outside the RT-PCR recommended window period, reported re-infection, or those lost to follow-up, 814 (64.2%) patients were considered eligible for the analysis of residual symptoms (Fig. 1, Additional file 1: Fig. S3). Questionnaires 2 and 3 were conducted 40 (31-59) days and 102 (63-150) days post symptom onset, respectively. No difference in sociodemographic data and frequency of positive RT-PCR were observed between the included (n=814) and excluded (n=454) participants (Additional file 1: Table S1). Among the included participants, 412 tested positive (COVID-19 group) and 402 tested negative (non-COVID-19 group) for SARS-CoV-2. Demographic characteristics for the COVID and non-COVID groups were as follows, respectively: a median age of 36 (IQR) and 34 (IQR) years, female gender of 55% and 64%, mild disease in 84% and 99% (Table 1). More patients were hospitalized in the COVID-19 group compared to the non-COVID-19 group (15.9% vs 1.5%, respectively, Table 1). Follow-up time was 3.3 months for the COVID group and 3.7 months for the non-COVID group (Additional file 1: Fig. S4).

• Download figure
• Open in new tab

Fig 1.

Flowchart of the study population.

After one month post disease onset, per the CDC definition for long COVID (September 16, 2021), 122/412 (29.6%) individuals from the COVID group reported residual symptoms and were classified as long COVID cases, while the remaining 290 individuals were fully recovered. From the non-COVID group, residual symptoms were reported by only 24 (6%) individuals (Table 1). Among long COVID cases, 57 (13.2%) presented with more than two residual symptoms.

Within the COVID group, fatigue (56, 13.7%), olfactory disorder (42, 9.9%), myalgia (36, 8.7%), gustatory disorder (27, 6.6%), and headache (26, 6.1%) were the residual symptoms most frequently reported (Fig. 2). These symptoms started mainly during the acute phase. Other symptoms not reported during the acute phase, such as memory loss and hair loss, were reported by the patients with long COVID (Additional file 1: Table S2). Compared to those who recovered, the long COVID group had more women (63.1% vs. 52.1%) and older individuals [40 (32-51) vs. 35 (28-47) years] (Table 2). Hospitalization for acute disease was comparable between long COVID (21/122, 17.2%) and recovered patients (44/290, 15.2%).

• Download figure
• Open in new tab

Fig. 2:

Frequency of acute and residual symptoms for COVID-19 and non-COVID-19 cases.

The risk of long COVID increased with age and was significant for persons 50 years of age or older (OR 2.44, 95% CI 1.29-4.66). Individuals with > five symptoms in the acute phase (OR 3.15, 95% CI 1.37-8.55) and females (OR 1.55, 95% CI 0.99-2.44) were more likely to develop long COVID (Table 3).

Co-occurrence of long COVID symptoms was also observed. Fatigue was reported by at least 50% of those that complained of gustatory dysfunction, anorexia, dysphonia, chest pain, headache, breathlessness, or myalgia. Moreover, olfactory dysfunction was reported by 80% of participants with gustatory dysfunction (Additional file 1: Fig. S5).

Finally, we have evaluated the impact of long COVID on the quality of life. The EQ-5D-3L questionnaire was administered to 102 out of 122 patients. Fifty-seven patients (55.8%) reported alteration in at least one dimension of QoL, and 41 patients (41.1%) had an impact in the dimension of pain and depression (Additional file 1: Table S3).

DISCUSSION

We have followed RT-PCR positive and negative patients with COVID-like symptoms from the first days post symptom onset to 63-150 days post symptom onset to determine the prevalence of long COVID-19. Long COVID occurred in almost one-third of test-positive cases, the majority with mild acute disease, compared to 6% of negative patients with residual symptoms, supporting the association between SARS-CoV-2 infection and residual symptoms. The risk of long COVID increased with age > 50 years old, female gender, and the development of > five symptoms during the acute phase. Together these findings demonstrate that residual symptoms after mild disease were mainly associated with COVID-19 with well-defined demographic and clinical risk factors.

The proportion of patients with COVID-19 who developed long COVID has varied from 7.5% to 89% [1, 2, 28, 29]. Most studies only included patients who tested positive for SARS-CoV-2. One strength of our study is the inclusion of a comparator group of symptomatic patients, recruited in the same time/location, who tested negative by SARS-CoV-2 RT-PCR. Additionally, most symptoms investigated in the follow-up questionnaires were evaluated at the time of recruitment, in a blinded manner, prior to the SARS-CoV-2 test result. The inclusion of a control group is important considering that many residual symptoms attributed to long COVID, such as fatigue and headache, are nonspecific and could be triggered or aggravated by stress and psychosocial problems connected to the global health crisis [11-13]. Indeed, we observed that non-confirmed COVID-19 cases reported similar residual symptoms after acute illness, albeit at a much lower frequency. Few studies have included a control group composed of symptomatic patients that tested negative for SARS-CoV-2 [14, 30]. In a cohort of healthcare workers, olfactory disorders and hair loss were related to long COVID while positive and negative cases both had similar frequencies of exhaustion/burnout and fatigue [14]. In a population-based digital retrospective cohort including outpatients and well-matched controls, 62 symptoms were associated with long COVID [30]. The inclusion of a control group is even more valuable for hospitalized cases, considering the increased risk of sequelae associated with iatrogenic procedures for treating severe disease [15]. Together, these findings highlight the importance of including a control group when determining the frequency of sequelae to avoid overestimating long COVID cases.

We observed a similar proportion of long COVID in groups with mild and moderate/severe disease [16,17]. We enrolled a small number of severe COVID-19 cases and therefore could not conclude an association between disease severity and sequelae. Severe COVID-19 increases the risk of long COVID by 1.2 to 8x among hospitalized cases compared to those not hospitalized [18]. Nonetheless, the finding that long COVID occurs in a significant proportion of individuals after mild disease highlights its potential impact on the healthcare system, as COVID-19 variants and sub-variants continue to spread worldwide.

Fatigue was the most frequent sequelae and occurred isolated or associated with other clinical manifestations. As previously reported [19], we also observed a vast impact of long COVID on the quality of life. Although the mechanism is unknown, an exacerbation of the immunological response and multisystemic involvement [20] seems to be involved. Studies investigating the pathogenesis of long COVID are essential to improve treatment and attenuate the impact.

Similar to previous studies [3, 9, 17, 21-23, 30], we found that long COVID was more prevalent in women and could be attributed to a greater propensity for women to go to a clinic [22]. Indeed, females represented 55% of the COVID group and 64% of the non-COVID group in our study. Sex hormone differences in immune response [24] and autoimmunity triggered by SARS-CoV-2 have been suggested to be involved in the disease pathogenesis of long COVID [23]. Other studies have found that individuals with more symptoms during the acute phase were at a higher risk for developing long COVID [9, 14]. There are conflicting results regarding age in the risk for developing long COVID. In a cohort of healthcare workers in Switzerland, the majority of whom had mild disease, young age was associated with a higher risk for developing long COVID [14], in contrast to our findings. Additional prospective studies including multicenter cohorts with larger sample sizes and older patients should be performed to evaluate if the risk for developing long COVID differs among age groups, racial groups, and ethnicities. Prospective studies to develop predictive models and algorithms should be performed for the early detection of long COVID cases.

Long COVID has different definitions. We have used the CDC’s definition for long COVID (September 16, 2021), that includes persistence of symptoms after four weeks of the onset of disease. Recently, a WHO-coordinated Delphi consensus established a period of more than three months after COVID-19 onset for the case definition of long COVID [25]. In our study, only 445 of the calls were performed three months after disease onset. By this definition, long COVID was detected in 68/216 (31.5%) of our patients. Residual symptoms were also observed in 17/229 (7.4%) of the non-COVID-19 patients. As observed in our study, the prevalence of long COVID may vary between studies in the absence of a universal consensus to define long COVID [4]. This impacts the estimation of the prevalence of long COVID cases worldwide.

This study has some limitations. The loss to follow-up was around 36% of patients and may have influenced the estimates of residual symptoms. Similar demographic and clinical characteristics were observed among patients that were included and the ones that were lost to follow-up. In addition, most participants were young, with mild disease, which does not permit generalizing these findings to the elderly and those with severe disease.

Moreover, the participants were aware of their diagnosis of COVID-19 when questionnaire 3 was applied, which may have led to an overestimation of persistent symptoms. Finally, the short time to follow-up did not allow for an analysis of the duration of long COVID.

CONCLUSIONS

Long COVID was detected in 29.6% of patients with mild COVID-19 disease, with older age, female sex, and polysymptomatic acute disease as the main risk factors for persistent symptoms. Estimating the long COVID prevalence is important for preparing the healthcare system to assist and guide these patients. Further studies should be conducted to evaluate the impact of different variants of SARS-CoV-2 on long COVID and the potential impact of vaccines in reducing residual symptoms.

DECLARATIONS